Pichamol Jirapinyo1, Christopher C Thompson1. 1. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND AND AIMS: Primary obesity surgery endoluminal (POSE) is a primary endoscopic bariatric therapy focusing on gastric remodeling. The original POSE procedure involved placement of full-thickness plications in the fundus. Here we aim to assess the feasibility, safety, and efficacy of a novel POSE procedure that involves plications of only the gastric body to reduce the width and length of the stomach. METHODS: This was a pilot study of patients who underwent a distal POSE procedure with gastric body plications for the treatment of obesity. Outcomes included technical success rate, serious adverse event (AE) rate, and efficacy of this novel POSE procedure at inducing weight loss and improving obesity-related comorbidities. RESULTS: Ten patients (6 women, age 52 ± 20 years) underwent a distal POSE procedure. Baseline body mass index was 38.1 ± 6.2 kg/m2. The technical success rate was 100%. An average of 21 ± 4 plications were placed per case (6 ± 2 for distal belt, 10 ± 3 for suspenders, 4 ± 2 for proximal belt, and 3 ± 1 for fillers). The gastroesophageal junction was pulled distally by 3.0 ± 1.6 cm. The gastric body was shortened by 11.0 ± 5.1 cm, representing a 59% reduction. The serious AE rate was 0%. At 6 months, patients experienced 15.0% ± 7.1% total weight loss (TWL). All patients achieved at least 5% TWL, and 8 patients (80%) achieved at least 25% excess weight loss. Hypertension, diabetes, GERD, and obstructive sleep apnea improved after the procedure. CONCLUSIONS: This novel POSE procedure, focusing on gastric body plication and sparing the fundus, is technically feasible and appears to be safe and effective for the treatment of obesity.
BACKGROUND AND AIMS: Primary obesity surgery endoluminal (POSE) is a primary endoscopic bariatric therapy focusing on gastric remodeling. The original POSE procedure involved placement of full-thickness plications in the fundus. Here we aim to assess the feasibility, safety, and efficacy of a novel POSE procedure that involves plications of only the gastric body to reduce the width and length of the stomach. METHODS: This was a pilot study of patients who underwent a distal POSE procedure with gastric body plications for the treatment of obesity. Outcomes included technical success rate, serious adverse event (AE) rate, and efficacy of this novel POSE procedure at inducing weight loss and improving obesity-related comorbidities. RESULTS: Ten patients (6 women, age 52 ± 20 years) underwent a distal POSE procedure. Baseline body mass index was 38.1 ± 6.2 kg/m2. The technical success rate was 100%. An average of 21 ± 4 plications were placed per case (6 ± 2 for distal belt, 10 ± 3 for suspenders, 4 ± 2 for proximal belt, and 3 ± 1 for fillers). The gastroesophageal junction was pulled distally by 3.0 ± 1.6 cm. The gastric body was shortened by 11.0 ± 5.1 cm, representing a 59% reduction. The serious AE rate was 0%. At 6 months, patients experienced 15.0% ± 7.1% total weight loss (TWL). All patients achieved at least 5% TWL, and 8 patients (80%) achieved at least 25% excess weight loss. Hypertension, diabetes, GERD, and obstructive sleep apnea improved after the procedure. CONCLUSIONS: This novel POSE procedure, focusing on gastric body plication and sparing the fundus, is technically feasible and appears to be safe and effective for the treatment of obesity.
Authors: Ben Gys; Philip Plaeke; Bas Lamme; Thierry Lafullarde; Niels Komen; Anthony Beunis; Guy Hubens Journal: Obes Surg Date: 2019-09 Impact factor: 4.129
Authors: Sérgio Barrichello; Diogo Turiani Hourneaux de Moura; Eduardo Guimaraes Hourneaux de Moura; Pichamol Jirapinyo; Anna Carolina Hoff; Ricardo José Fittipaldi-Fernandez; Giorgio Baretta; João Henrique Felício Lima; Eduardo N Usuy; Leonardo Salles de Almeida; Flavio M Ramos; Felipe Matz; Manoel Dos Passos Galvão Neto; Christopher C Thompson Journal: Gastrointest Endosc Date: 2019-06-19 Impact factor: 9.427
Authors: Shelby Sullivan; James M Swain; George Woodman; Marc Antonetti; Nestor De La Cruz-Muñoz; Sreeni S Jonnalagadda; Michael Ujiki; Sayeed Ikramuddin; Jaime Ponce; Marvin Ryou; Jason Reynoso; Rajiv Chhabra; G Brent Sorenson; Wendell K Clarkston; Steven A Edmundowicz; J Christopher Eagon; Daniel K Mullady; Daniel Leslie; Thomas E Lavin; Christopher C Thompson Journal: Obesity (Silver Spring) Date: 2016-12-21 Impact factor: 5.002
Authors: J C Espinós; R Turró; G Moragas; A Bronstone; J N Buchwald; F Mearin; A Mata; H Uchima; J Turró; S Delgado-Aros Journal: Obes Surg Date: 2016-05 Impact factor: 4.129
Authors: Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427
Authors: Nitin Kumar; Barham K Abu Dayyeh; Gontrand Lopez-Nava Breviere; Manoel P Galvao Neto; Nicole P Sahdala; Sohail N Shaikh; Robert H Hawes; Christopher J Gostout; Mahesh K Goenka; Jorge R Orillac; Alonso Alvarado; Pichamol Jirapinyo; Natan Zundel; Christopher C Thompson Journal: Surg Endosc Date: 2017-10-26 Impact factor: 4.584
Authors: Andrea Telese; Vinay Sehgal; Cormac G Magee; S Naik; S A Alqahtani; L B Lovat; Rehan J Haidry Journal: Clin Transl Gastroenterol Date: 2021-06-18 Impact factor: 4.488
Authors: Maria Valeria Matteo; Marika D'Oria; Vincenzo Bove; Giorgio Carlino; Valerio Pontecorvi; Marco Raffaelli; Daniela Chieffo; Alfredo Cesario; Giovanni Scambia; Guido Costamagna; Ivo Boškoski Journal: J Pers Med Date: 2021-12-04